Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19318496rdf:typepubmed:Citationlld:pubmed
pubmed-article:19318496lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:19318496lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:19318496lifeskim:mentionsumls-concept:C0281361lld:lifeskim
pubmed-article:19318496lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:19318496lifeskim:mentionsumls-concept:C0045093lld:lifeskim
pubmed-article:19318496lifeskim:mentionsumls-concept:C1424316lld:lifeskim
pubmed-article:19318496lifeskim:mentionsumls-concept:C1130454lld:lifeskim
pubmed-article:19318496lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:19318496lifeskim:mentionsumls-concept:C1521996lld:lifeskim
pubmed-article:19318496lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:19318496pubmed:issue8lld:pubmed
pubmed-article:19318496pubmed:dateCreated2009-4-16lld:pubmed
pubmed-article:19318496pubmed:abstractTextGemcitabine is a promising adjuvant treatment for patients with resected pancreatic adenocarcinoma and its use in combination with radiotherapy is under exploration. Human equilibrative nucleoside transporter 1 (hENT1) and human concentrative nucleoside transporter (hCNT) 1 and 3 are the major transporters responsible for 2',2'-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. The aim of this study was to determine patients' outcome according to the expression of hENT1 and hCNT3 in tumoral cells after postoperative gemcitabine-based chemoradiation regimen.lld:pubmed
pubmed-article:19318496pubmed:languageenglld:pubmed
pubmed-article:19318496pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19318496pubmed:citationSubsetIMlld:pubmed
pubmed-article:19318496pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19318496pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19318496pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19318496pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19318496pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19318496pubmed:statusMEDLINElld:pubmed
pubmed-article:19318496pubmed:monthAprlld:pubmed
pubmed-article:19318496pubmed:issn1078-0432lld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:CassCarol ECElld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:DevièreJacque...lld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:MackeyJohn...lld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:SalmonIsabell...lld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:LaiRaymondRlld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:YoungJamesJlld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:Van...lld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:DemetterPiete...lld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:PeetersMarcMlld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:PolusMarcMlld:pubmed
pubmed-article:19318496pubmed:authorpubmed-author:MaréchalRapha...lld:pubmed
pubmed-article:19318496pubmed:issnTypePrintlld:pubmed
pubmed-article:19318496pubmed:day15lld:pubmed
pubmed-article:19318496pubmed:volume15lld:pubmed
pubmed-article:19318496pubmed:ownerNLMlld:pubmed
pubmed-article:19318496pubmed:authorsCompleteYlld:pubmed
pubmed-article:19318496pubmed:pagination2913-9lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:meshHeadingpubmed-meshheading:19318496...lld:pubmed
pubmed-article:19318496pubmed:year2009lld:pubmed
pubmed-article:19318496pubmed:articleTitleHuman equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.lld:pubmed
pubmed-article:19318496pubmed:affiliationDepartment of Gastroenterology and Hepato-Pancreatology, Gastrointestinal Cancer Unit, and Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. rmarecha@ulb.ac.belld:pubmed
pubmed-article:19318496pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19318496pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:2030entrezgene:pubmedpubmed-article:19318496lld:entrezgene
entrez-gene:64078entrezgene:pubmedpubmed-article:19318496lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19318496lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19318496lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19318496lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19318496lld:pubmed